
Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.
What To Know: The agreement includes $58 million in base funding over 24 months to support the onshoring of CD388 manufacturing in the United States, conduct a clinical trial to compare higher-concentration formulations, test different presentations, further evaluate activity in non-clinical models and begin developing protocols for expanded populations.